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Abstract
Background and Aims Tenofovir disoproxil fumarate
(TDF) demonstrated potent and sustainable antiviral effi-
cacy and a good safety profile in patients with chronic
hepatitis B (CHB) in controlled clinical trials. Real-world
data are important to confirm effectiveness and safety data
in patient populations encountered in routine clinical
practice.
Methods This non-interventional, prospective, 36-month
study included treatment-naı¨ve and treatment-experienced
patients with CHB initiating their first TDF regimen
(monotherapy or combination therapy) in routine clinical
practice in France. Clinical, virologic, biochemical, com-
pliance, and safety data were collected.
Results Data from 440 consecutive patients from 58
centers were analyzed. The majority of the cohort was maleOn behalf of the VIREAL Group. The list of members in the group is
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(71 %), hepatitis B ‘‘e’’ antigen-negative (HBeAg–)
(74 %), and treatment-experienced (56 %); 11 % were
aged C65 years; and comorbidities were reported in 39 %.
After 12 months, 92 % of the overall cohort achieved
virologic response (HBV DNA \69 IU/mL) which was
maintained to 36 months (96 %); virologic response was
achieved by [90 % of patients irrespective of HBeAg
status, age, or prior treatment history. At 36 months, 77 %
of patients had normal alanine aminotransferase levels.
Fourteen patients lost hepatis B surface (HBs) antigen, and
seven seroconverted to anti-HBs. TDF was well tolerated
over the 36-month study, including in 14 women who
became pregnant during the study. Median estimated
glomerular filtration rate did not change markedly from
baseline irrespective of prior treatment history.
Conclusions TDF demonstrated potent virologic and
biochemical responses across a broad range of patients
reflective of routine clinical practice. The safety profile was
consistent with results from pivotal trials.
Keywords HBV  Tenofovir  Routine practice  Real-
world
Introduction
Chronic infection with hepatitis B virus (HBV) represents a
major global health problem, responsible for around
780,000 deaths worldwide, largely through serious liver-
related sequelae [1]. Chronic HBV infection (CHB)
prevalence varies widely, being highest in sub-Saharan
Africa and East Asia, where 5–10 % of the adult popula-
tion is chronically infected. HBV infection is becoming a
public health concern in countries where prevalence was
previously reduced due to factors including increased
migration from countries with intermediate/high HBV
prevalence [2]. Although recent data on HBV prevalence in
France are lacking, a 2004 national survey estimated hep-
atitis B surface antigen (HBsAg) prevalence was 0.68 %,
corresponding to 280,821 chronic carriers [3]. A 2001
French survey of patient mortality related to hepatitis B and
C estimated that 1507 deaths were attributed to HBV
infection, corresponding to 2.5 deaths per 100,000 persons
[4].
Many studies have demonstrated the correlation
between viral load and the risk of developing cirrhosis and
hepatocellular carcinoma (HCC) [5–8]. As it is not possible
to eradicate HBV [9], CHB treatment aims to provide
sustained suppression of HBV replication, thus preventing
disease progression and death. Tenofovir disoproxil
fumarate (TDF) is a potent nucleotide analog recom-
mended as a first-line therapy for CHB in international and
national guidelines [9–11]. Pivotal randomized controlled
trials have reported high efficacy and a favorable safety
profile with TDF treatment for up to 8 years in treatment-
naı¨ve and treatment-experienced patients [12–15], with
associated fibrosis regression and cirrhosis [14]. No drug
resistance to TDF has been observed.
Published data from real-world studies with TDF, which
include the highly diverse patients encountered in routine
practice, are lacking, and are mostly retrospective, but are
required in order to confirm and expand upon the results of
clinical trials [16, 17]. The prospective, non-interventional,
multicenter VIREAL study investigated the use of TDF in
routine clinical management of CHB in France, and eval-
uated its effectiveness and safety in a ‘‘real-world’’ cohort
of patients.
Patients and Methods
VIREAL is a multicenter, non-interventional, prospective
study to assess the long-term effectiveness and safety of
TDF treatment in a real-life cohort of patients with CHB
managed in routine clinical settings in France. Participating
sites included teaching hospitals, general hospitals, and
private practices specializing in CHB to provide a repre-
sentative cross section of CHB management. Patients were
enrolled at 58 centers across France. Recruitment took
place between June 2009 and April 2010, and the database
was locked in October 2013.
The study was conducted in accordance with Good
Epidemiological Practice guidelines, was approved by the
French Medical Board, and was authorized by the National
Computers and Privacy Commission. Patients gave written
consent for the collection of anonymized medical data from
their medical files.
Study Population
The study enrolled treatment-naı¨ve or treatment-experi-
enced patients C18 years of age with hepatitis B ‘‘e’’
antigen (HBeAg)-negative (HBeAg–) or HBeAg-positive
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(HBeAg?) CHB, initiating a first prescription of TDF at
enrollment. TDF treatment initiation was at the treating
physician’s discretion. Key exclusion criteria included
prior treatment with TDF, evidence of HCC, or co-infec-
tion with human immunodeficiency virus (HIV), hepatitis
C virus, or hepatitis D virus.
Study Assessments and Data Collection
Data on safety and on the clinical, laboratory, and virologic
course of TDF-treated patients from the routine testing/
evaluations conducted by the treating physician were cap-
tured. Study-specific laboratory tests, resistance monitor-
ing, or prespecified visits were not required. As visit times
varied between practices, patient assessments were
assigned a nominal visit month of 3, 6, 12, 18, 24, 30, and
36 months based on the number of days since the baseline
visit within a visit window of ± 3 months of the nominal
visit month. Data were collected via an electronic case
report form and included the following: patient demo-
graphics; anti-HBV treatment history; viral genotype;
serum HBV DNA levels; HBeAg and HBsAg; alanine
aminotransferase (ALT); other routine laboratory parame-
ters; renal function tests (serum creatinine, creatinine
clearance [CrCl], estimated glomerular filtration rate
[eGFR] calculated by Cockcroft–Gault formula at the
beginning of the study which was replaced by the Chronic
Kidney Disease Epidemiology Collaboration formula);
liver histology and progression of liver-related complica-
tions; resistance to anti-HBV therapy; adverse events (AEs)
and serious AEs; pregnancy; adherence to therapy; and
therapy interruptions.
Virologic response was defined as HBV DNA\69 IU/
mL. Adherence was assessed using a six-question ques-
tionnaire completed by the patient at each visit, which was
first applied in the field of hypertension [18]. The total
number of ‘‘yes’’ answers defined the level of adherence:
0 = good; 1–2 = minor problems; and [3 = poor
adherence.
Statistical Analysis
Mean, standard deviation (SD), median, range, or first and
third quartile (Q1, Q3) were calculated for continuous
variables, together with the total number of observations
and the number of non-missing and missing values. For
categorical variables, number and percent of patients are
reported. Missing data were excluded from the efficacy
analysis. The safety analysis included all treated patients.
Comparative analyses were performed using Pearson’s
Chi-square test for qualitative variables, and Student’s t test
for analyses of variance for quantitative variables. Non-
parametric tests were used in the case of a non-normal
distribution. Statistical analysis was performed using SAS
(Version 9.1).
Results
In total, 440 patients were prospectively enrolled. Of these,
328 completed the study, and 112 discontinued the study
[49 (46.7 %) patients were lost to follow-up; 27 (24.1 %)
were discontinued at the investigator’s discretion; 12
(10.7 %) patients made the decision to discontinue; 10
patients died (8.9 %); seven (6.3 %) patients discontinued
due to an adverse drug reaction; and seven (6.3 %) were
withdrawn as they did not fit the inclusion/exclusion
criteria].
The overall population was predominantly male and
around three-quarters were HBeAg– (Table 1). The largest
proportion of patients was of European decent (38.6 %).
Mode of HBV infection was unknown in almost half of
patients (46 %). Where this was known (n = 237), the
most commonly cited routes were the following: at birth or
during early childhood (54.4 %); family exposure
(18.1 %); nosocomial infection (10.5 %); sexual exposure
(6.3 %); and drug use (2.5 %).
Just over half of the patients (n = 258) were treatment-
experienced, with around two-thirds having previously
received an adefovir (ADV)-containing regimen:
monotherapy or in combination with lamivudine (LAM)
(Table 2). The majority (179/258) of the treatment-expe-
rienced patients were switched directly to TDF. Seventy-
nine patients were not receiving treatment at baseline and
the washout period of previous treatment was variable. Of
the treatment-experienced patients, 64 (24.8 %) terminated
previous therapy and 38 (14.7 %) initiated TDF due to
persistent viremia/suboptimal response and viral relapse
(defined as a confirmed increase in HBV DNA level of
more than 1 log10 IU/mL compared with the nadir (lowest
value) HBV DNA level on therapy) [9]. Mean baseline
HBV DNA levels were lower in treatment-experienced
patients than treatment-naı¨ve patients (Table 2). A higher
proportion of treatment-experienced patients had unde-
tectable viral load (HBV DNA \69 IU/mL) at baseline
compared with treatment-naı¨ve patients (61.1 vs. 5.5 %,
respectively, Table 2). Viral genotype was known for only
7 % of patients so is not included in the analysis (Table 1).
Baseline ALT levels varied widely [median (range) 35
(7–828) IU/Ml]. At baseline, more than half of patients had
normal ALT (ALT\upper limit of normal) (Table 2). The
proportion of patients with normal ALT was higher in
treatment-experienced compared with treatment-naı¨ve
patients (71.3 vs. 35.3 %, respectively), and in HBeAg–
compared with HBeAg? patients (59.5 vs. 42.9 %,
respectively).
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Around two-thirds of patients had a report of liver
biopsy at baseline. The majority had no/minimal fibrosis
(METAVIR score F0–F1) or moderate fibrosis (F2);
14.4 % had cirrhosis (F4). Clinical signs of cirrhosis were
reported in 17 patients (co-existing signs were possible):
ascites (n = 4), esophageal varices (n = 13), and spleno-
megaly (n = 10).
The most commonly reported comorbidities were
hypertension and diabetes mellitus; prior renal insuffi-
ciency was reported in 14 patients, and 14 patients had a
history of liver (n = 11) or renal (n = 3) transplantation.
In all, 122 patients (27.7 %) had baseline eGFR\90 mL/
min/1.73 m2, with 24 of these patients having a baseline
eGFR\60 mL/min/1.73 m2; no patient had baseline eGFR
\30 mL/min/1.73 m2.
TDF Treatment
At study initiation, most treatment-naı¨ve patients (91.2 %)
received TDF as monotherapy, with the remainder
receiving TDF in combination with LAM. The majority of
treatment-experienced patients (63.4 %) received initial
treatment with TDF as monotherapy, with the remainder
receiving TDF in combination with entecavir (ETV)
(19.8 %) or LAM (21.3 %). Most patients remained on
TDF monotherapy for the entire study duration, with 70
receiving add-on medication, predominantly ETV (n = 15)
or LAM (n = 45). Overall 17 patients switched to an
alternative treatment (ETV n = 14; LAM n = 3).
Virologic Response
By month 12, 92 % of the overall population with available
data (n = 308) had HBV DNA\69 IU/mL, rising to 96 %
at 36 months (n = 259). A greater proportion of HBeAg–
patients compared with HBeAg? patients achieved HBV
DNA\69 IU/mL by month 12 (90.0 vs. 80.3 %, respec-
tively). Irrespective of HBeAg status, treatment history, or
whether patients received TDF as monotherapy or in
combination, [90 % of patients with available data
achieved HBV DNA\69 IU/mL by 36 months of treat-
ment with TDF (Fig. 1; Table 3). Prior treatment regimen
did not affect response;[90 % of patients who were pre-
viously treated with LAM ? ADV (n = 82) or with ETV
(n = 21) achieved HBV DNA\69 IU/mL by month 36. A
total of 27 patients had one or more resistance-associated
variants (RAVs) at baseline, including those associated
with LAM and ADV. Three of these patients had HBV
DNA \69 IU/mL at baseline and at final visit; all
remaining patients achieved a virologic response during
treatment, the majority by month 3, and maintained this
response to their last visit. Of the 18 patients with resis-
tance-associated mutations at baseline and HBV DNA
levels available at baseline and final visit, 13 had unde-
tectable HBV DNA at the final visit. No correlation was
observed between adherence score and virologic response.
Older age did not appear to affect response; of the 26
patients aged C65 years at baseline who completed
36 months of treatment, all (100 %) achieved HBV DNA
Table 1 Baseline characteristics
Characteristic N = 440
Age, years, mean (SD) 45.3 (14.3)
C65 years, n (%) 48 (10.9)
Male, n (%) 312 (70.9)
Geographic descent, n (%)
Europe 170 (38.6)
Middle East 21 (4.8)
Asia Pacific 101 (23.0)
North Africa 44 (10.0)
Sub-Saharan Africa 87 (19.8)









Patients with cirrhosis, n (%)a 68 (15.5)
Liver biopsy performed, n (%) 298 (67.7)








Diabetes mellitus 40 (9.1)
Cardiovascular disease 16 (3.6)
Rheumatic disease 15 (3.4)
Renal insufficiency/dysfunction 14 (3.2)
Malignant disease 10 (2.3)
Neuropsychiatric disease 9 (2.1)
Other 104 (23.6)
SD standard deviation
a History of cirrhosis as defined by the investigator; method not
further specified
b Where reported (n = 170). Multiple comorbidities were possible
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\69 IU/mL versus 95.3 % of patients aged \65 years
(n = 222).
Among 167 patients with HBV DNA \69 IU/mL at
baseline, 13 patients experienced virologic breakthrough
(defined as patients with baseline HBV DNA\69 IU/mL
and an HBV DNA of C69 IU/mL for at least one post-
baseline visit) over the course of the study. The annual
rate of virologic breakthrough was 3.6, 3.6, and 0.6 % at
12, 24, and 36 months, respectively. For 11 of these 13
patients, breakthrough was transient. All patients with
virologic breakthrough continued TDF and completed the
study. No baseline RAVs were reported for the 13 patients
with virologic breakthrough. A minor problem of
compliance was reported for four patients, and the treat-
ment adherence questionnaire was not completed for eight
patients.
Biochemical Response
Mean (SD) ALT improved from 67.2 (95.07) IU/mL at
baseline to 31.3 (18.01) IU/mL at month 36. The propor-
tion of patients with normal ALT levels increased steadily
to 76.8 % (74.6 % treatment-naı¨ve; 77.7 % treatment-ex-
perienced) by 12 months, and this proportion was main-
tained to 36 months (78.0 % overall; 75.0 % treatment-
naı¨ve; 79.4 % treatment-experienced).
Table 2 Baseline characteristics by prior treatment history
Characteristic Treatment-naı¨ve patients Treatment-experienced patients All patients
n/N (%) 182/440 (41.4) 258/440 (58.6) 440/440 (100)
HBeAg-negative, n/n (%) 121/419 (28.9) 183/419 (43.7) 304/419 (74.1))
HBV DNA, IU/mL, mean (SD) 3.41 9 107 (1.15 9 108) 3.76 9 106 (2.05 9 107) 1.63 9 107 (7.70 9 107)
HBV DNA, IU/mL, median (Q1–Q3)a 4.1 9 104 (2270–6.8 9 106) 20 (12–735) 3.6 9 103 (40.0–3.95 9 105)
HBV DNA C2000 IU/mL, n/n (%) 36/181 (19.9) 16/257 (6.2) 52/438 (11.9)
Normal ALT (BULNb), n/n (%) 61/171 (35.3) 179/251 (71.3) 240/422 (56.9)
HBV DNA\69 IU/mL, n/n (%) 10/182 (5.5) 157/258 (60.9) 167/440 (38.0)
Prior treatment regimen, n (%)c
IFN or PEG-IFN ± other – 68/258 (28.3) –
LAM monotherapy – 28/258 (9.7) –
ADV monotherapy – 21/258 (6.6) –
ETV monotherapy – 13/258 (4.7) –
LAM ? ADV – 109/258 (32.2) –
LAM ? ADV ? other – 38/258 (23.6) –
Otherd – 7/258 (7.4) –
Reason for initiating TDF, n (%)
Persistent viremia/suboptimal response – 64/258 (24.8) –
Relapse – 38/258 (14.7) –
Resistance development – 9/258 (3.5) –
Adverse reaction – 10/258 (3.9) –
Non-adherence – 5/258 (1.9) –
Other (not specified) – 141/258 (54.7) –
Laboratory and biochemical parameters
Serum creatinine, median (range), lmol/L 77.0 (37.0, 1034.0) 83.0 (29.0, 416.0) 79.70 (29.0, 197.4)
CrCl, median (range), mL/min 112.9 (52.4, 226.0) 90.5 (29.3, 200.9) 98.8 (29.3, 226.0)
eGFR, median (range), mL/min/1.73 m2 107.7 (56.5, 148.2) 91.7 (33.3, 149.7) 99.1 (33.3, 149.7)
ALT, median (range), U/L 59.0 (7.0, 2174.0) 29.0 (8.0, 521.0) 35.0 (7.0, 828.0)
ADV adefovir, ALT alanine aminotransferase, CrCl creatinine clearance, eGFR estimated glomerular filtration rate, HBeAg hepatitis B ‘‘e’’
antigen, ETV entecavir, IFN interferon, LAM lamivudine, PEG-IFN pegylated interferon, SD standard deviation, TDF tenofovir disoproxil
fumarate, ULN upper limit of normal
a Data were missing for one patient in the treatment-naı¨ve group and one patient in the treatment-experienced group
b ALT upper limit of normal was B43 U/L for males and B34 for females
c Multiple responses possible; 26 patients are included in both the interferon-containing regimen and LAM ? ADV ? other group
d Includes unspecified treatment and treatment with telbivudine ? ADV, ETV ? ADV, and ETV ? LAM
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Serologic Response
Of the 80 patients who were HBeAg? at baseline with C1
additional HBeAg status test at some stage during the
study, 36 (45 %) lost HBeAg and 20 achieved HBeAg
seroconversion during the study (five additional patients
were anti-HBe? at baseline). Three patients who lost
HBeAg and seroconverted to anti-HBe? during the study
reconverted and were HBeAg?, anti-HBe- at their final
study visit.
During the study, 14 patients (3 %) lost HBsAg. (Three
HBeAg? at baseline, 10 HBeAg–, and one with unknown
HBeAg status at baseline). Of the 14 patients with HBsAg
loss, five were treatment-naı¨ve and nine were treatment-
experienced (ADV ? LAM, n = 4; ADV ? LAM ? -
PEG-IFN, n = 2; ADV ? PEG-IFN, n = 2; ADV ?
ETV, n = 1). The cumulative rate of HBsAg loss was
0.96 % in the first year, 2.89 % in year 2, and 3.37 % in
year 3. Seven patients (Five HBeAg–) achieved HBsAg
seroconversion during the course of the study. The
Fig. 1 Virologic response over time. a By HBeAg status; b by prior treatment status. HBeAg hepatitis B e antigen
Table 3 Proportion of patients
achieving virologic response
(HBV DNA\69 IU/mL)
according to therapy and HBV
level at baseline
Baseline treatment/treatment group Baseline Month 12 Month 24 Month 36
Treatment-naı¨ve patients (n = 182), n (%)
TDF monotherapy
All (n = 166) 10 (6) 99 (91) 104 (96) 94 (95)
HBV DNA\69 IU/mL at BL (n = 11) 10 (100) 5 (100) 3 (100) 3 (100)
HBV DNA[69 IU/mL at BL (n = 155) 0 (0) 94 (90) 101 (96) 91 (95)
TDF combination therapy
HBV DNA[69 IU/mL at BL (n = 16) 0 (0) 8 (89) 4 (100) 2 (67)
Treatment-experienced patients (n = 258), n (%)
TDF monotherapy
All (n = 166) 90 (55) 99 (89) 95 (94) 94 (96)
HBV DNA\69 IU/mL at BL (n = 91) 90 (100) 58 (97) 52 (96) 51 (96)
HBV DNA[69 IU/mL at BL (n = 75) 0 (0) 41 (80) 43 (91) 43 (96)
TDF combination therapy
All (n = 92) 67 (73) 76 (96) 63 (93) 58 (98)
HBV DNA\69 IU/mL at BL (n = 67) 67 (100) 55 (98) 49 (94) 44 (100)
HBV DNA[69 IU/mL at BL (n = 25) 0 (0) 21 (91) 14 (88) 14 (93)
BL baseline, TDF tenofovir disoproxil fumarate
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cumulative rate of seroconversion was 0.72 % in the first
year, 1.20 % in year 2, and 1.68 % in year 3.
Safety
TDF was well tolerated over the 36-month study. In total,
41 patients (9.3 %) reported 68 AEs considered by the
physician to be related to TDF (Table 4). There was no
difference in the proportions of treatment-naı¨ve and treat-
ment-experienced patients reporting adverse events (8.2 vs.
10.1 %, P = 0.711). Of the16 serious AEs reported in 16
patients, nine were considered to be related to TDF (visual
impairment, nausea, asthenia, gait disturbance, weight
decrease, muscular weakness, musculoskeletal pain,
depression, psoriasis, all n = 1).
There were 10 deaths during the study [HCC n = 1;
leukemia n = 2; breast cancer n = 1; suicide post-liver
transplantation n = 1; stroke n = 1; post-liver transplan-
tation complications n = 1; cholangiocarcinoma n = 1;
and end-stage liver disease (hepatic encephalopathy n = 1;
spontaneous bacterial peritonitis n = 1)]. No deaths were
considered to be related to TDF.
Sixteen pregnancies were reported during the study. The
majority of these patients had become pregnant while
taking TDF with one case where TDF was administered
prophylactically. Follow-up data were available for 14
cases. Of these, the mean age of the mothers was 29 years,
and 57 % (n = 8) were HBeAg?; METAVIR fibrosis
scores (where available) were F0 in one patient, F1 in three
patients, and F2 in six patients. Median duration of TDF
exposure during pregnancy was 35 weeks (range
5–39 weeks). Therapy was interrupted in four patients
(obstetricians’ decision n = 2; patient’s decision n = 1;
HBsAg loss n = 1) at weeks 12, 16, 23, and 25 of preg-
nancy. One patient discontinued treatment at week 5 (ob-
stetrician’s decision). Two HBeAg? mothers had HBV
DNA[106 IU/mL at delivery (one TDF discontinuation;
one non-adherence). Vaccination and immunoprophylaxis
according to the French guidelines were recommended for
all newborns. Median gestational age at delivery was
39 weeks (range 34–40 weeks). No AEs related to TDF
were observed, no neonatal complications arose, and no
birth defects were reported. Complications during preg-
nancy, labor, or postpartum were: n = 1; premature labor
controlled by medication and n = 2; postpartum hemor-
rhage. Five patients reported breastfeeding, with three
breastfeeding while receiving TDF without any adverse
consequences for the babies up to 1 year. No infant was
reported to be HBsAg? at 9 months of age. Of five infants
with anti-HBs testing, all were anti-HBs? (84–308 IU/
mL).
During the course of the study, median change in CrCl
and serum creatinine remained relatively stable over
36 months of treatment, regardless of prior treatment
(Table 5). Serum phosphorus levels were also stable over
the study period.
Mean eGFR declined slightly over the treatment period
(Table 6). Older patients (C65 years) and patients previ-
ously treated with ADV-containing regimens had lower
eGFR at baseline, which declined slightly or remained
stable over the treatment period (Fig. 2a). When subdi-
vided by baseline eGFR, mean eGFR declined slightly over
time in patients with baseline CrCl C90 mL/min/1.73 m2,
and increased slightly in patients with mild or moderate
renal impairment at baseline (Fig. 2b). Overall, 65 (15 %)
had a decline in eGFR of C20 % versus baseline and 26
patients (6 %) had a decline in eGFR of C30 % versus
baseline (Table 7). Prior treatment did not have a
Table 4 Adverse events considered by the physician to be related to
TDF
Patients (n)





Serious adverse eventsa 9









Abnormal renal function testsc 4
Renal failure 3
Renal impairment 2
Renal tubular disorder 2
Muscle spasms 2
Discontinuation of TDF due to adverse eventsd 23
TDF tenofovir disoproxil fumarate
a Serious adverse events comprised visual impairment, nausea,
asthenia, gait disturbance, weight decrease, muscular weakness,
musculoskeletal pain, depression, psoriasis, (all n = 1)
b Abdominal pain includes the MedRA preferred terms abdominal
pain upper (n = 1) and abdominal pain (n = 7)
c Abnormal results included creatinine renal clearance decreased
(n = 2) and blood creatinine increased (n = 2)
d Reasons for discontinuation in [1 patient (multiple reasons per
patient were possible): nausea (n = 5) vomiting (n = 4); asthenia
(n = 3); renal failure (n = 3); diarrhea (n = 2); abdominal pain
(n = 2); renal impairment (n = 2); renal tubular disorder (n = 2)
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significant effect on the proportion of patients with at least
a 20 or 30 % decline in eGFR. However, significantly
fewer patients in the treatment-naı¨ve versus treatment-ex-
perienced group and in the group with no prior ADV
therapy versus prior ADV therapy had an eGFR value of
\60 mL/min/1.73 m2 for at least one post-baseline visit
(P\ 0.001 for both).
Renal endpoints were observed in approximately 3 % of
patients: five patients had a serum creatinine increase of at
least 0.5 mg/dL from baseline and two patients had a
decreased creatinine clearance. Three cases of renal failure,
two cases of renal impairment, and two cases of renal tubular
dysfunction were reported as mild or moderate AEs. None of
these patients had a reported history of renal impairment.
One patient had been treated previously with ADV and
LAM, one had been treated previously with ADV, two had
been treated previously with ADV and LAM with LAM
therapy continuing during the study. One patient had dia-
betes, two had hypercholesterolemia, and two were of older
age (67 years and 72 years). TDF was discontinued in all
patients. No renal-related serious AEs were reported.
Major Liver-Associated Events
Two cases of confirmed HCC and three cases of suspected
HCC arose during the course of the study (months 3 and
12, and months 24 and 36, respectively). All patients were
reported to have cirrhosis at baseline; both patients with
confirmed HCC also had clinical signs or symptoms of
advanced liver disease at baseline (esophageal varices in
one patient; esophageal varices and ascites in the second).
Two patients died due to complications of end-stage liver
disease (hepatic encephalopathy n = 1; spontaneous bac-
terial peritonitis n = 1). Neither death was considered to be
related to TDF.
Discussion
In this study of CHB patients managed in routine clinical
practice in France, treatment with TDF resulted in sus-
tained virologic suppression. Virologic suppression was
maintained over 36 months, irrespective of HBeAg status
Table 5 Mean change from
baseline in creatinine clearance,
serum creatinine, and serum
phosphorus (all patients with
available data)
Baseline Month 12 Month 24 Month 36
Creatinine clearance (n)
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or treatment history. In this diverse patient population,
treatment was well tolerated with a safety profile similar to
that reported in clinical trials. In addition, efficacy data
from this study compare favorably to those reported in the
pivotal clinical trials of TDF in CHB.
The diversity of the patient population in the VIREAL
cohort compared with that in clinical trials is reflected in
the wide variation of baseline parameters including ALT
and viral load, the varied geographical origin of the
patients, and the high proportion of patients with reported
Table 6 Change in estimated glomerular filtration rate from baseline according to prior treatment status
Treatment group Baseline,
(n)
Change in eGFR (CKD-EPI) from baseline to:
Month 12,
n, median (range) (mL/min/
1.73 m2)
Month 24,
n, median (range) (mL/min/
1.73 m2)
Month 36,
































































ADV adefovir, CKD-EPI chronic kidney disease epidemiology collaboration, eGFR estimated glomerular filtration rate
P values calculated using Fisher’s exact test (two-sided)
Fig. 2 Mean estimated glomerular filtration rate. a By age and treatment history; b by baseline creatinine clearance (CrCl) category. ADV
adefovir, CKD-EPI chronic kidney disease epidemiology collaboration, CrCl creatinine clearance, eGFR estimated glomerular filtration rate
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comorbidities. Despite this, the efficacy data from the
current study compare favorably to those reported in the
pivotal clinical trials of TDF in CHB. Following the initial
randomized study period of 48 weeks, patients included in
the pivotal clinical trials of TDF were enrolled in an open-
label study and treated for 7 additional years. After
26 months of treatment with TDF, 99 % of HBeAg–
patients and 93 % of HBeAg? patients achieved HBV
DNA \69 IU/mL [13] in the on-treatment population,
which is similar to that included in VIREAL. Further data
have demonstrated that virologic response is maintained to
5 years, with 99 % of HBeAg– and 97 % of HBeAg?
patients achieving HBV DNA\29 IU/mL [14]. Recently
presented 8-year data from this study show that this
response is maintained, with a good safety profile and no
evidence of virologic resistance [15].
Our data are similar to those reported in a prospective/
retrospective real-world European study including 374
treatment-naı¨ve patients, where 97 % of patients had
undetectable HBV DNA (PCR negative) after 4 years of
TDF treatment [16]. Patients in this European cohort and
the majority of patients in the pivotal clinical trials were
treatment-naı¨ve whereas around half of the patients in the
VIREAL cohort were treatment-experienced.
By month 36 of the current study, 94 % of treatment-
experienced patients achieved HBV DNA \69 IU/mL,
including all 18 patients with resistance-associated variants
at baseline. These results are consistent with data from a
randomized trial of TDF or TDF/emtricitabine in patients
who previously had an incomplete response to ADV [19].
This study demonstrated that response was not influenced
by the presence of ADV- or LAM-associated mutations. In
contrast, retrospective analysis of patients treated in Ger-
many and The Netherlands found that although LAM
resistance did not influence antiviral response, the presence
of ADV resistance impaired TDF efficacy (100 vs. 52 %
probability of HBV DNA\69 IU/mL, respectively) [20].
The variability in these results demonstrates that further
research is required before the relationship between ADV
resistance and TDF response is fully understood.
Numerous studies have shown an association between
HBV DNA levels and disease progression [5, 8] and that
long-term HBV DNA suppression can reduce serious liver-
related sequalae [14, 21] reinforcing the importance of
HBV DNA suppression in the treatment of CHB.
Overall, 78 % of VIREAL patients had normal ALT
levels after 36 months of TDF treatment, again similar to
that seen in pivotal trials [3, 12, 15]. Serologic response in
VIREAL was also similar to that seen in clinical trials,
with 45 % of HBeAg? patients losing HBeAg in VIR-
EAL compared with 34 % in the clinical trial population
after 3 years [13]. In all, 14 patients in VIREAL lost
HBsAg during the course of the study, and seven of these
patients also seroconverted to anti-HBs. Interestingly,
these patients were predominantly HBeAg– at baseline,
while all except one patient who showed HBsAg loss/
seroconversion in the clinical trial population were
HBeAg?. This may partly result from the proportion of
HBeAg– patients in this cohort compared with the clinical
trial population.
TDF was well tolerated over 36 months in VIREAL,
with a safety profile similar to that reported in clinical
trials. Treatment-related serious AEs were low, and the
majority of patients stayed on TDF treatment until their
last visit. There was no statistical difference in the
number of AEs related to TDF reported in treatment-
naı¨ve and treatment-experienced patients. Although there
was a slight decline in mean serum creatinine, CrCl, and
eGFR, statistical comparison to baseline should be
viewed with caution due to the high proportion of
missing data. Furthermore, a decrease in eGFR is
expected in patients over time due to aging. We observed
Table 7 Proportion of patients with a decline in estimated glomerular filtration rate of C20 % compared with baseline, C30 % compared with
baseline and eGFR values\60 mL/min/1.73 m2











eGFR decline C 20 % versus baseline,
n (%)
65 (15) 22 (12) 43 (17) 31 (17) 34 (13)
P = 0.220 P = 0.221
eGFR decline C30 % versus baseline,
n (%)
26 (6) 8 (4) 18 (7) 10 (6) 16 (6)
P = 0.308 P = 1.00
eGFR\60 mL/min/1.73 m2,
n (%)
48 (11) 3 (2) 45 (17) 35 (20) 13 (5)
P\ 0.001 P\ 0.001
ADV adefovir, eGFR estimated glomerular filtration rate
P values calculated using Fisher’s exact test (two-sided)
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that significantly fewer treatment-naı¨ve patients had an
eGFR value of \60 mL/min/1.73 m2 compared with
treatment-experienced patients. This could be due to the
fact that treatment-experienced patients have received
treatment for a longer duration than patients who were
receiving TDF as their first treatment. While serum
creatinine levels are commonly used markers of renal
function, other urinary and serum proteins may be ear-
lier, more accurate markers of renal toxicity [22].
However, testing of such biomarkers is not routinely
used in clinical practice, and creatinine clearance was
therefore used in this real-life study to monitor renal
function. In all, only seven cases of renal AEs were
reported, all of which were of mild-to-moderate intensity,
and were managed by TDF discontinuation.
Our study adds to the increasing data on the use of
TDF during pregnancy. In VIREAL, treatment with TDF
during pregnancy, including during the first trimester, was
not associated with any AEs during pregnancy, compli-
cations during labor, neonatal complications, or birth
defects. TDF has been assigned pregnancy category B by
the Food and Drug Administration, compared with cate-
gory C for LAM, ADV, and ETV. A recent review
examining data on the use of TDF in pregnancy in both
HIV and HBV infection [23] together with that from the
1800 pregnancies included in the Antiretroviral Pregnancy
Registry, concluded that the safety data for TDF during
pregnancy are generally reassuring for pregnancy out-
comes and for lack of congenital or other severe anoma-
lies in exposed infants.
The limitations of this study are those generally related
to non-interventional, uncontrolled, observational studies.
There was a variable amount of missing data which was
particularly notable for some parameters. The reasons for
this loss may include the treating physician not perform-
ing certain tests routinely, patients being lost to follow-up,
or database entry errors. In addition, sites utilized their
local laboratory for testing which means that inter-labo-
ratory variation is possible. The data presented here is
reflective of the practice of the clinicians included in the
study and their individual monitoring procedures. As a
result, some parameters of interest, such as bone mineral
density and bone biomarkers, which are known to be
associated with antiretroviral therapy [24], were not
specifically assessed in this study. However, the main
strength of the study is the diversity of the patient pop-
ulation meaning the results are relevant to real-world
patients and to other countries with similar management
strategies and HBV demographics.
In conclusion, TDF shows significant and sustained
antiviral activity against HBV and a favorable safety and
tolerability profile in a diverse population of patients
managed in routine clinical practice, including treatment-
experienced patients, older patients, and patients with
advanced liver disease or renal insufficiency. The effec-
tiveness and safety results of TDF in clinical practice are
similar to those reported in clinical trials.
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Appendix: VIREAL Group
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Roulot, Bobigny; Dr. Saillard, Pointe A Pitre; Dr. Truchi,
Nice; Prof. Zarski, Grenoble; Prof. Zoulim, Lyon.
References
1. World Health Organization. Hepatitis B Fact Sheet No 204.
Updated July 2014. http://www.who.int/mediacentre/factsheets/
fs204/en/. Accessed June 2015.
2. Chu JJ, Wo¨rmann T, Popp J, et al. Changing epidemiology of
hepatitis B and migration—a comparison of six Northern and
North-Western European countries. Eur J Public Health.
2013;23:642–647.
3. Zarski JP. Epide´miologie de l’he´patite chronique B. Presse Med.
2006;35:304–307.
4. Marcellin P, Pequignot F, Delarocque-Astagneau E, et al. Mor-
tality related to chronic hepatitis B and chronic hepatitis C in
France: evidence for the role of HIV coinfection and alcohol
consumption. J Hepatol. 2008;48:200–207.
5. Chen G, Lin W, Shen F, Iloeje UH, London WT, Evans AA. Past
HBV viral load as predictor of mortality and morbidity from
HCC and chronic liver disease in a prospective study. Am J
Gastroenterol. 2006;101:1797–1803.
6. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma
across a biological gradient of serum hepatitis B virus DNA level.
JAMA. 2006;295:65–73.
7. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting
cirrhosis risk based on the level of circulating hepatitis B viral
load. Gastroenterology. 2006;130:678–686.
8. Iloeje UH, Yang HI, Jen CL, et al. Risk and predictors of mor-
tality associated with chronic hepatitis B infection. Clin Gas-
troenterol Hepatol. 2007;5:921–931.
9. European Association for the Study of the Liver. EASL clinical
practice guidelines: management of chronic hepatitis B. J
Hepatol. 2012;57:167–185.
10. Dhumeaux D. Prise en charge des personnes infecte´es par les
virus de l’he´patite B ou de l’he´patite C. Rapport de Recom-
mandations 2014. http://www.sante.gouv.fr/IMG/pdf/Rapport_
Prise_en_charge_Hepatites_2014.pdf. Accessed June 2015.
11. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009.
Hepatology. 2009;50:661–662.
12. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil
fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl
J Med. 2008;359:2442–2455.
13. Heathcote EJ, Marcellin P, Buti M, et al. Three-year efficacy and
safety of tenofovir disoproxil fumarate treatment for chronic
hepatitis B. Gastroenterology. 2011;140:132–143.
14. Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during
treatment with tenofovir disoproxil fumarate for chronic hepatitis
B: a 5-year open-label follow-up study. Lancet. 2013;381:
468–475.
15. Marcellin P, Gane EJ, Flisiak R, et al. Long term treatment with
tenofovir disoproxil fumarate for chronic hepatitis B infection is
safe and well tolerated and associated with durable virologic
response with no detectable resistance: 8 year results from two
phase 3 trials. Hepatology. 2014;60:313A.
16. Lampertico P, Soffrendi R, Yurdaydin C, et al. Four years of
tenofovir monotherapy for NUC naı¨ve field practice European
patients suppresses HBV replication in most patients with a
favourable renal safety profile but does not prevent HCC in
patients with or without cirrhosis. Hepatology. 2013;58:653A.
17. van Bo¨mmel F, Zoutendijk R, de Man R, et al. A European field
study of the efficacy and safety of tenofovir disoproxil fumarate
(TDF) monotherapy in patients with prior failure to other
nucleoside/nucleotide analogues. J Hepatol. 2012;57:S544.
18. Girerd X, Hanon O, Anagnostopoulos K, Ciupek C, Mourad JJ,
Consoli S. Assessment of antihypertensives compliance using a
self-administered questionnaire: development and use in hyper-
tension clinics. Presse Med. 2001;30:1044–1048.
19. Berg T, Marcellin P, Zoulim F, et al. Tenofovir is effective alone
or with emtricitabine in adefovir-treated patients with chronic-
hepatitis B virus infection. Gastroenterology. 2010;139:1207–
1217.
20. van Bo¨mmel F, de Man RA, Wedemeyer H, et al. Long-term
efficacy of tenofovir monotherapy for hepatitis B virus-monoin-
fected patients after failure of nucleoside/nucleotide analogues.
Hepatology. 2010;51:73–80.
21. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with
chronic hepatitis B and advanced liver disease. N Engl J Med.
2004;351:1521–1531.
22. Lock E. Sensitive and early markers of renal injury: where are we
and what is the way forward? Toxicol Sci. 2010;116:1–4.
23. Wang L, Kourtis AP, Ellington S, Legardy-Williams J, Bulterys
M. Safety of tenofovir during pregnancy for the mother and fetus:
a systematic review. Clin Infect Dis. 2013;57:1773–1781.
24. Fontana RJ. Side effects of long-term oral antiviral therapy for
hepatitis B. Hepatology. 2009;49(Suppl):S185–S195.
Dig Dis Sci (2016) 61:3072–3083 3083
123
